Risk factors associated with antibiotic treatment failure of Buruli ulcer.
Conclusions:There is a low rate of treatment failure in Australian BU patients treated with rifampicin-based oral combination antibiotic therapy. Our study raises the possibility that treatment failure risk may be increased in males, body weight >90kg, immune suppression and in those taking rifampicin/clarithromycin antibiotic regimens but future pharmacokinetic and pharmacodynamics studies are required to determine the validity of these hypotheses.
PMID: 32571813 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: O'Brien DP, Friedman ND, Walton A, Hughes A, Athan E Tags: Antimicrob Agents Chemother Source Type: research
More News: Antibiotic Therapy | Australia Health | Biaxin | Buruli Ulcer | Chemotherapy | Clarithromycin | Microbiology | Study